Medivation is a biopharmaceutical company focused on the development and commercialization of therapies to treat diseases. Co.'s principal program is XTANDI® (enzalutamide) capsules, which is partnered with Astellas Pharma Inc. (Astellas). The program had received regulatory approval from the U.S. Food and Drug Administration for the treatment of post-chemotherapy mCRPC patients. Together with Astellas, Co. is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC, and in patients with breast cancer.
MDVN — Key Stats (updated Friday, December 6, 10:25 AM)
I recently heard from an old friend. He told me of his battle with colon cancer.
His doctors had given him a 30% chance of surviving, but thanks a new generation of powerful anti-cancer drugs, his cancer has been in remission for nearly five years now.
You probably know someone like that, too.
Simply put, a diagnosis of cancer is no longer a death sentence. In fact, so much groundbreaking research is being done that doctors are starting to envision a future in which cancer is merely a setback.
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.